BRAF and neoplasm: Additionally, related to the tumor laterality, no differences in median PFS (between patients either cfDNA RAS/BRAF mutations at any time or NGS mutations or baseline microsatellite instability/defective MMR vs patients without these alterations) were found, either in the total population or in the panitumumab subgroup of patients with left-sided tumors (Supplementary Fig S1 and Fig. S2, respectively).